The Patent Finder

Terms ending in 2044

Genentech, Inc.

Every in-force patent on Genentech, Inc.'s record whose computed term ends in 2044, whoever holds it now. Soonest term end first, then patent number.
PatentTitleHolderStatusExpiresConfidence
US 12,770,713Generative Protein Design with Composable Energy-Based Models
In force
 · Medium confidence
Genentech, Inc.In forceMedium confidence
US 12,338,460Method for Generating T Cell Lineage Populations from Stem/Progenitor Cells
In force
 · High confidence
Genentech, Inc.In forceHigh confidence
US 12,749,555Multipole Moment Based Coarse Grained Representation of Antibody Electrostatics
In force
 · Medium confidence
Genentech, Inc.In forceMedium confidence
US 12,398,953Rapid Depressurization Controlled Ice Nucleation in Pharmaceutical Freeze-Drying
In force
 · High confidence
Purdue Research FoundationIn forceHigh confidence
US 12,516,118Dosing for Treatment with ANTI-CD20/ANTI-CD3 Bispecific Antibodies and ANTI-CD79B Antibody Drug Conjugates
In force
 · High confidence
Genentech, Inc.In forceHigh confidence
5 of 5 patents shown. Soonest term end first, then patent number.
4 of these are in force and held by Genentech, Inc..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited